Plasma proteomic pattern as biomarkers for ovarian cancer

Y. W. Lin, C. Y. Lin, H. C. Lai, J. Y. Chiou, C. C. Chang, M. H. Yu, T. Y. Chu

研究成果: 雜誌貢獻文章

39 引文 (Scopus)

摘要

Early detection of ovarian cancer remains a challenge. Pathologic changes within an organ might be reflected in proteomic patterns in serum or plasma. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry (MS) protein profiling and artificial intelligence. The study included 35 women with ovarian cancer and 30 age-matched disease-free controls. For plasma protein signature analysis, the protein chip array surface-enhanced laser desorption/ionization (SELDI) analysis was performed. The strong anion exchange (SAX) and weak cation exchange (WCX) chips were used for analysis. After a training analysis by SAX and WCX protein chips, learning algorithm and clustering analysis was performed to reach a discriminate pattern of protein signature. SELDI mass spectroscopy was highly reproducible in detecting ovarian tumor-specific protein profiles. Four specific protein peaks were identified in plasma of women with ovarian cancer, but not in controls, with relative molecular masses of 6190.48, 5147.06, 11522.6, and 11537.7 d. Two peaks, with Mr 5295.5 and 8780.48 d, were present in plasma of control but not in women with ovarian cancer. A sensitivity of 90-96.3% and specificity of 100% for this studied cases and controls were reached. This study clearly demonstrates that the combined technology of SELDI-MS and artificial intelligence is effective in distinguishing protein expression between normal and ovary cancer plasma. The identified gained and lost protein peaks in plasma may provide as candidate proteins to be used for the detection or monitoring ovarian cancer.
原文英語
頁(從 - 到)139-146
頁數8
期刊International Journal of Gynecological Cancer
16
發行號SUPPL. 1
DOIs
出版狀態已發佈 - 二月 2006
對外發佈Yes

指紋

Proteomics
Ovarian Neoplasms
Biomarkers
Protein Array Analysis
Proteins
Artificial Intelligence
Anions
Mass Spectrometry
Lasers
Antiporters
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Early Detection of Cancer
Cluster Analysis
Cations
Blood Proteins
Learning
Technology
Serum
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

引用此文

Plasma proteomic pattern as biomarkers for ovarian cancer. / Lin, Y. W.; Lin, C. Y.; Lai, H. C.; Chiou, J. Y.; Chang, C. C.; Yu, M. H.; Chu, T. Y.

於: International Journal of Gynecological Cancer, 卷 16, 編號 SUPPL. 1, 02.2006, p. 139-146.

研究成果: 雜誌貢獻文章

Lin, Y. W. ; Lin, C. Y. ; Lai, H. C. ; Chiou, J. Y. ; Chang, C. C. ; Yu, M. H. ; Chu, T. Y. / Plasma proteomic pattern as biomarkers for ovarian cancer. 於: International Journal of Gynecological Cancer. 2006 ; 卷 16, 編號 SUPPL. 1. 頁 139-146.
@article{5a5756854a0449bfbc9f3eeff732860a,
title = "Plasma proteomic pattern as biomarkers for ovarian cancer",
abstract = "Early detection of ovarian cancer remains a challenge. Pathologic changes within an organ might be reflected in proteomic patterns in serum or plasma. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry (MS) protein profiling and artificial intelligence. The study included 35 women with ovarian cancer and 30 age-matched disease-free controls. For plasma protein signature analysis, the protein chip array surface-enhanced laser desorption/ionization (SELDI) analysis was performed. The strong anion exchange (SAX) and weak cation exchange (WCX) chips were used for analysis. After a training analysis by SAX and WCX protein chips, learning algorithm and clustering analysis was performed to reach a discriminate pattern of protein signature. SELDI mass spectroscopy was highly reproducible in detecting ovarian tumor-specific protein profiles. Four specific protein peaks were identified in plasma of women with ovarian cancer, but not in controls, with relative molecular masses of 6190.48, 5147.06, 11522.6, and 11537.7 d. Two peaks, with Mr 5295.5 and 8780.48 d, were present in plasma of control but not in women with ovarian cancer. A sensitivity of 90-96.3{\%} and specificity of 100{\%} for this studied cases and controls were reached. This study clearly demonstrates that the combined technology of SELDI-MS and artificial intelligence is effective in distinguishing protein expression between normal and ovary cancer plasma. The identified gained and lost protein peaks in plasma may provide as candidate proteins to be used for the detection or monitoring ovarian cancer.",
keywords = "Ovarian cancer, Protein chip, SELDI-TOF mass spectrometry",
author = "Lin, {Y. W.} and Lin, {C. Y.} and Lai, {H. C.} and Chiou, {J. Y.} and Chang, {C. C.} and Yu, {M. H.} and Chu, {T. Y.}",
year = "2006",
month = "2",
doi = "10.1111/j.1525-1438.2006.00475.x",
language = "English",
volume = "16",
pages = "139--146",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Plasma proteomic pattern as biomarkers for ovarian cancer

AU - Lin, Y. W.

AU - Lin, C. Y.

AU - Lai, H. C.

AU - Chiou, J. Y.

AU - Chang, C. C.

AU - Yu, M. H.

AU - Chu, T. Y.

PY - 2006/2

Y1 - 2006/2

N2 - Early detection of ovarian cancer remains a challenge. Pathologic changes within an organ might be reflected in proteomic patterns in serum or plasma. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry (MS) protein profiling and artificial intelligence. The study included 35 women with ovarian cancer and 30 age-matched disease-free controls. For plasma protein signature analysis, the protein chip array surface-enhanced laser desorption/ionization (SELDI) analysis was performed. The strong anion exchange (SAX) and weak cation exchange (WCX) chips were used for analysis. After a training analysis by SAX and WCX protein chips, learning algorithm and clustering analysis was performed to reach a discriminate pattern of protein signature. SELDI mass spectroscopy was highly reproducible in detecting ovarian tumor-specific protein profiles. Four specific protein peaks were identified in plasma of women with ovarian cancer, but not in controls, with relative molecular masses of 6190.48, 5147.06, 11522.6, and 11537.7 d. Two peaks, with Mr 5295.5 and 8780.48 d, were present in plasma of control but not in women with ovarian cancer. A sensitivity of 90-96.3% and specificity of 100% for this studied cases and controls were reached. This study clearly demonstrates that the combined technology of SELDI-MS and artificial intelligence is effective in distinguishing protein expression between normal and ovary cancer plasma. The identified gained and lost protein peaks in plasma may provide as candidate proteins to be used for the detection or monitoring ovarian cancer.

AB - Early detection of ovarian cancer remains a challenge. Pathologic changes within an organ might be reflected in proteomic patterns in serum or plasma. The objective of this study was to identify new plasma biomarkers in ovarian cancer patients using mass spectrometry (MS) protein profiling and artificial intelligence. The study included 35 women with ovarian cancer and 30 age-matched disease-free controls. For plasma protein signature analysis, the protein chip array surface-enhanced laser desorption/ionization (SELDI) analysis was performed. The strong anion exchange (SAX) and weak cation exchange (WCX) chips were used for analysis. After a training analysis by SAX and WCX protein chips, learning algorithm and clustering analysis was performed to reach a discriminate pattern of protein signature. SELDI mass spectroscopy was highly reproducible in detecting ovarian tumor-specific protein profiles. Four specific protein peaks were identified in plasma of women with ovarian cancer, but not in controls, with relative molecular masses of 6190.48, 5147.06, 11522.6, and 11537.7 d. Two peaks, with Mr 5295.5 and 8780.48 d, were present in plasma of control but not in women with ovarian cancer. A sensitivity of 90-96.3% and specificity of 100% for this studied cases and controls were reached. This study clearly demonstrates that the combined technology of SELDI-MS and artificial intelligence is effective in distinguishing protein expression between normal and ovary cancer plasma. The identified gained and lost protein peaks in plasma may provide as candidate proteins to be used for the detection or monitoring ovarian cancer.

KW - Ovarian cancer

KW - Protein chip

KW - SELDI-TOF mass spectrometry

UR - http://www.scopus.com/inward/record.url?scp=33645375391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645375391&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2006.00475.x

DO - 10.1111/j.1525-1438.2006.00475.x

M3 - Article

C2 - 16515582

AN - SCOPUS:33645375391

VL - 16

SP - 139

EP - 146

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - SUPPL. 1

ER -